A lawsuit was filed on behalf of investors in Agile Therapeutics Inc (NASDAQ:AGRX) shares over alleged securities laws violations and NASDAQ:AGRX investors should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 01/09/2017 -- An investor, who purchased NASDAQ:AGRX shares, filed a lawsuit in New Jersey against Agile Therapeutics Inc over alleged Securities Laws violations.
Investors who purchased shares of Agile Therapeutics Inc (NASDAQ:AGRX) have certain options and for certain investors are short and strict deadlines running. Deadline: March 7, 2017. NASDAQ:AGRX investors should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The plaintiff claims that between March 9, 2016 and January 3, 2017 the Defendants allegedly failed to disclose that the Twirla contraceptive patch had an efficacy rating that fell below peer group standards, that over half of patients in its "Secure" Phase 3 Study discontinued the study early, that the Twirla patch therefore allegedly had a slight chance of FDA approval, and that, as a result of the foregoing, Defendants' statements about Agile Therapeutics' business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On January 3, 2017, Agile Therapeutics Inc (NASDAQ:AGRX) announced top-line results from its Phase 3 SECURE clinical trial of Twirla®, its investigational low-dose combined hormonal contraceptive patch. The study, which was initiated at the request of the FDA, comes after the FDA rejected Agile's initial marketing application back in 2013. The Company cited "positive top-line results" in the study, yet reported that almost 2% of subjects experienced "serious adverse events" including "deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy and depression." Shares of Agile Therapeutics Inc (NASDAQ:AGRX) declined to as low as $1.82 per share on January 4, 2017.
On January 6, 2017, NASDAQ:AGRX shares closed at $2.69 per share.
Those who purchased shares of Agile Therapeutics Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego